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Abstract
F-box proteins and DCAF proteins are the substrate binding subunits of SCF (Skp1-Cul1-F-box
protein) and CRL4 (Cul4-RING protein Ligase) ubiquitin ligase complexes, respectively. Using
affinity purification and mass spectrometry, we determined that the F-box protein FBXO11
interacts with CDT2, a DCAF protein that controls cell cycle progression, and recruits CDT2 to
the SCFFBXO11 complex to promote its proteasomal degradation. In contrast to most SCF
substrates, which exhibit phosphodegrondependent binding to F-box proteins, CDK-mediated
phosphorylation of Thr464 present in the CDT2 degron inhibits recognition by FBXO11. Finally,
our results show that the functional interaction between FBXO11 and CDT2 is evolutionary
conserved from worms to humans and plays an important role in regulating the timing of cell
cycle exit.
INTRODUCTION
Unidirectional progression through the cell cycle depends on the specific, rapid, and
temporally-controlled proteolysis of key cellular regulators by the ubiquitin-proteasome
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system (UPS). E3 ubiquitin ligases confer substrate specificity to the UPS. Among the
eukaryotic E3s, Cullin-RING Ligases (CRLs) constitute the largest family of multi-subunit
ubiquitin ligases (Petroski and Deshaies, 2005). The archetypes of the CRL family are the
CRL1/SCF (Skp1-Cul1-F-box protein) E3s, which utilize different F-box proteins (69 in
humans) as receptors that bind substrates. Significantly, multiple F-box proteins are mutated
or display altered expression in a variety of diseases, including cancer (Frescas and Pagano,
2008; Lipkowitz and Weissman, 2011; Skaar et al., 2009a).
FBXO11 is conserved from nematodes to mammals and both human FBXO11 and its worm
ortholog (DRE-1) form functional SCF ubiquitin ligases (Fielenbach et al., 2007). DRE-1
deletion causes larva lethality, whereas DRE-1 mutation induces precocious terminal
differentiation of epidermal stem cells and altered temporal patterning of gonadal
outgrowths, indicating an important role for DRE-1 in controlling cell fate determination
(Fielenbach et al., 2007).
In mice, homozygous mutation of Fbxo11 results in cleft palate defects, facial clefting, and
perinatal lethality. Moreover, haploinsufficient mutant alleles cause otitis media, a disorder
that affects approximately 15 % of children (Hardisty-Hughes et al., 2006). Accordingly,
genetic studies show a correlation between particular SNP variants of FBXO11 and the
development of chronic otitis media (Segade et al., 2006). Finally, FBXO11 inactivating
mutations contribute to the pathogenesis of diffuse large B-cell lymphoma (DLBCL)
through BCL6 stabilization, a B-cell specific oncoprotein (Duan et al., 2012). FBXO11
mutations are also present in other human cancers, such as colon, lung, ovary, and head and
neck tumors (Kan et al., 2010; Cancer Genome Atlas Research Network, 2011; Stransky et
al., 2011; Yoshida et al., 2011; Lohr et al., 2012). These data suggest that FBXO11 may
function as a tumor suppressor, whose loss of function contributes to the pathogenesis of
DLBCL (via BCL6accumulation) and other cancers (through the stabilization of
unidentified pro-oncogenic substrates).
In an effort to elucidate FBXO11 functions, we have identified CDT2 as a novel interactor
of FBXO11. CDT2 belongs to the family of WD40 repeat-containing DCAF proteins that
work as substrate receptors for CRL4 ubiquitin ligases. CDT2 is conserved from nematodes
to humans and plays fundamental roles in the regulation of the S-phase of the cell cycle by
controlling the degradation of SET8, CDT1, and p21 under normal and stress conditions
(Abbas and Dutta, 2011; Abbas et al., 2010; Abbas et al., 2008; Centore et al., 2010; Havens
and Walter, 2011; Higa et al., 2006; Jorgensen et al., 2011; Kim et al., 2008; Oda et al.,
2010).
In this study, we demonstrate that SCFFBXO11 targets CDT2 for proteasomal degradation,
elucidating a critical and conserved control mechanism for the timing of cell cycle exit.
RESULTS
To identify SCFFBXO11 substrates, FLAG-HA-tagged FBXO11 was transiently expressed in
HEK-293T cells. To block the degradation of SCFFBXO11 substrates and increase their co-
purification with FBXO11, cells were either co-transfected with CUL1(1–385), a dominant
negative CUL1 mutant, or treated for four hours with the proteasome inhibitor MG132.
Purifications of FLAG-HA-FBXO10, a paralog of FBXO11, were used as a control.
FBXO11 and FBXO10 complexes were immunopurified for analysis by Multidimensional
Protein Identification Technology (MudPIT) (Florens and Washburn, 2006). Peptides
corresponding to CDT2 were specifically identified in FBXO11 immunoprecipitates from
cells in which either CUL1(1–385) was co-expressed or MG132 was added (Table S1).
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To investigate whether the binding between CDT2 and FBXO11 is specific, FLAG-tagged
CDT2 was expressed in HeLa cells and immunoprecipitated with an anti-FLAG resin. We
found that FLAG-tagged CDT2 was able to co-immunoprecipitate endogenous FBXO11
and, as expected, endogenous CUL4 and DDB1, but it was unable to co-immunoprecipitate
any of the nine additional F-box proteins tested (Fig. S1A). Furthermore, endogenous CDT2
co-immunoprecipitated endogenous FBXO11, except when CDT2 expression was silenced
by siRNA (Fig. 1A), proving that FBXO11 was co-immunoprecipitated via CDT2. In
contrast, when FBXO11 was depleted, CDT2 still co-immunoprecipitated CUL4 and DDB1,
but not FBXO11 (Fig. 1A).
Significantly, the FBXO11-CDT2 interaction is conserved through evolution as CDT-2 (the
C. elegans ortholog of CDT2) expressed in HeLa cells was able to immunoprecipitate both
endogenous human FBXO11 and exogenous C. elegans DRE-1 (Fig. S1B–C).
To test whether FBXO11 might regulate the degradation of CDT2, we used four different
siRNAs to reduce its expression in HeLa and U-2OS cells. Depletion of FBXO11 by all four
siRNAs induced an increase in both the steady state levels and stability of CDT2 (Fig. 1B–C
and Fig. S1D). In contrast, silencing of CDT2 did not induce changes in the abundance of
FBXO11 (Fig. 1D). These experiments indicate that, whereas SCFFBXO11 controls the
stability of CDT2, CRL4CDT2 does not control FBXO11 abundance.
We also observed that expression of FBXO11 induced the appearance of high molecular
weight species of CDT2, which are likely ubiquitylated forms of CDT2 (Fig. S1E).
Moreover, we reconstituted the ubiquitylation of CDT2 by FBXO11 in vitro.
Immunopurified FBXO11, but not FBXO11(ΔF-box), a mutant that is unable form an active
SCF complex, promoted the in vitro ubiquitylation of CDT2 when ubiquitin was present in
the reaction (Fig. 1E). Methylated ubiquitin inhibited the formation of the highest molecular
weight forms of CDT2, demonstrating that the high molecular weight forms of CDT2 are
indeed polyubiquitylated. These results support the hypothesis that FBXO11 directly
controls the ubiquitin-mediated degradation of CDT2.
To map the FBXO11 binding motif in CDT2, we generated CDT2 deletion mutants and
found that the FBXO11 binding motif of human CDT2 is present in a region between amino
acids 458 and 471 (Fig. S2A–C). Then, to further narrow down the FBXO11 interacting
region we mutagenized individual residues present in this 14 amino acid region of CDT2 to
either Asp or Ala (Fig. 2A). The only amino acid necessary for stable association between
CDT2 and FBXO11 was Thr464, and its mutation to either Ala or Asp strongly decreased
the ability of CDT2 to co-immunoprecipitate endogenous FBXO11 (Fig. 2B). Significantly,
Thr464 is conserved through evolution (Fig. S2D), and a CDT2(Thr464Ala) mutant
displayed a significantly longer half-life than wild type CDT2 (Fig. 2C and Fig. S2E).
Moreover, in contrast to wild type CDT2, CDT2(Thr464Ala) was not stabilized by FBXO11
silencing or MG132 (Fig. 2C and Fig. S2E).
Most often, phosphorylation of substrates is necessary for their binding to F-box proteins
(Cardozo and Pagano, 2004; Skaar et al., 2009a; Skaar et al., 2009b). Therefore, we
examined whether Thr464 phosphorylation of CDT2 plays a role in FBXO11 binding. To
this end, we generated a phospho-specific antibody against a peptide containing phospho-
threonine at position 464. This antibody recognized wild type CDT2, but not three different
CDT2 mutants in which Thr464 was substituted to Asp, Glu, or Ala (Fig. S2F). In addition,
λ-phosphatase treatment of immunopurified CDT2 or CDT2 silencing abolished recognition
of CDT2 by the phospho-specific antibody (Fig. S2F–G, Fig. 2D). These results show that
CDT2 is phosphorylated in vivo on Thr464.
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Interestingly, we also observed that the CDT2(Pro465Ala) mutant was not phosphorylated
in cultured cells, but it was still able to bind FBXO11 (Fig. S3A), suggesting that this
phosphorylation is not essential for CDT2 binding to FBXO11. To further investigate
whether phosphorylation affects the CDT2-FBXO11 interaction, we used immobilized,
synthetic peptides containing the FBXO11 binding sequence (aa 457–470 in human). While
non-phosphorylated peptide efficiently bound FBXO11 (but not FBXO1), a corresponding
peptide containing phosphorylated Thr464 displayed a strongly reduced ability to bind
FBXO11 (Fig. 2E), indicating that Thr464 phosphorylation inhibits the interaction between
the two proteins. Accordingly, CDT2 phosphorylated on Thr464 was not co-
immunoprecipitated with FBXO11 (Fig. 2F). Thus, the presence of unphosphorylated
Thr464 appears crucial for the binding of CDT2 to FBXO11, explaining why mutation of
Thr464 to either Ala (which eliminates Thr464) or Asp (which presumably mimics Thr464
phosphorylation) reduced the in vivo binding to FBXO11. Notably, although mutation of
Pro465 inhibits Thr464 phosphorylation, this mutation did not affect the CDT2-FBXO11
interaction.
The fact that mutation of Pro465 prevents Thr464 phosphorylation suggested that a proline-
directed kinase phosphorylates Thr464. As a first step in the identification of this kinase, we
treated cultured cells with a panel of kinase inhibitors. We found that two different CDK
inhibitors (RO-3306 and Roscovitine) reduced CDT2 phosphorylation on Thr464, whereas
SB203580 (a p38 inhibitor), D4476 (a CKI inhibitor), SB203580 (a p38 inhibitor), pp242 (a
mTOR inhibitor), PD98059 (an ERK inhibitor), GSK iX (a GSK inhibitor), U0126 (a MEK
inhibitor), DMAT (a CKII inhibitor), and LY293646 (a DNA-PK inhibitor) had no effect
(Fig. 3A and data not shown). Importantly, RO-3306 significantly reduced the half-life of
CDT2 (Fig. 3B) and increased the co-immunoprecipitation of endogenous FBXO11 with
FLAG-CDT2 (Fig. S3B), in agreement with the idea that phosphorylation of Thr464
stabilizes the protein. Moreover, both Cyclin B-Cdk1 and Cyclin A-Cdk2, but not Cyclin E-
Cdk2, phosphorylated CDT2 on Thr464 in vitro (Fig. 3C), even though all three Pro-
directed kinases were able to phosphorylate p27 on Thr187 (Fig. S3C). Finally, ERK2
(another proline-directed kinase) and Plk1 (another cell cycle regulatory kinase), failed to
phosphorylate CDT2 in vitro (Figs. 3C and S3D). These data suggest that CDK-dependent
phosphorylation of CDT2 blocks its interaction with FBXO11 and promote CDT2 stability.
We then sought to find the physiological conditions required for CDT2 degradation,
focusing our attention on conditions that inhibit CDK activity. We found that, in two
different immortalized cell lines (RPE1-hTERT and HaCaT), CDT2 levels dramatically
decreased after cell cycle withdraw obtained by serum starvation (Fig. 4A and Fig. S4A).
This decrease was dependent on FBXO11, as shown by CDT2 stabilization following
FBXO11 silencing (Fig. 4A and Fig. S4A) or inhibition of the proteasome with MG132 (not
shown). To further investigate the degradation of CDT2, we serum starved RPE1-hTERT
and HaCaT cells expressing either an empty virus, FLAG-tagged wild-type CDT2, or
FLAG-tagged CDT2(T464D). Wild-type CDT2 (both endogenous and exogenous) was
degraded after serum withdraw, while CDT2(T464D) remained stable (Fig. 4B and Fig.
S4B), in agreement with its inability to bind FBXO11 (Fig. 2B). Significantly, CDT2 was
phosphorylated on Thr464 in the presence of serum, but not in the absence of serum (Fig.
4C), supporting the notion that CDT2 degradation is blocked by Thr464 phosphorylation.
In order to confirm our results using a different stimulus that inhibits CDK activity and
induces cell cycle arrest, we used TGF-β, whose downstream target SMAD2 has been
proven to genetically interact with FBXO11 in a mouse model (Tateossian et al., 2009). We
observed that CDT2 levels decreased in two TGF-β–responsive cell lines (HaCaT and
MDA-MB-231), but not in the TGF-β–unresponsive T47-D cell line (Fig. 4D and Fig. S4C),
and this decrease was dependent on FBXO11 (Fig. 4D and Fig. S4D). Moreover, wild-type
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CDT2 was degraded in HaCaT cells upon TGF-β treatment, while CDT2(T464D) was not
(Fig. S4E). Finally, TGF-β treatment induced a decrease in the phosphorylation of CDT2 on
Thr464 (Fig. S4F). Thus, cell cycle exit induced by serum starvation or TGF-β affects the
phosphorylation and SCFFBXO11-dependent degradation of CDT2.
Inhibition of CDT2 degradation by FBXO11 depletion or expression of the stable
CDT2(T464D) mutant in cells deprived of serum or treated with TGFβ resulted in a
consistent decrease in SET8 levels; however, the effect on other CDT2 substrates (CDT1
and p21) was less consistent (Fig. 4A–B, Fig. S4A–B). Moreover, CDT2 stabilization
resulted in a consistent delay in cell cycle exit, as indicated by the percentage of cells in S
phase (Fig. 4E and Fig. S4G–I), slower kinetics of p27 accumulation (p27 is marker of G0/
G1), and the delayed disappearance of S-phase and mitotic cyclins (cyclin E and cyclin B,
respectively) (Fig. 4A–B and Fig. S4A–B). Wild type CDT2 produced intermediate effects
since, although degraded in response to serum withdraw, it was expressed at levels above
those of the endogenous protein (Fig. 4B). Taken together, these results indicate that
FBXO11-dependent degradation of CDT2 plays a role in controlling the timing of cell cycle
exit.
To validate our phenotypic observations in vivo, we used C. elegans as a genetic model to
examine the FBXO11-CDT2 interaction. C. elegans epidermal stem cells, called seam cells,
undergo various larval stage-specific patterns of proliferation and asymmetric cell division.
Early in L4, they cease dividing, exit the cell cycle, and fuse into a long syncytium along the
lateral midline. Finally, they differentiate and synthesize an adult-specific cuticular structure
called adult alae. dre-1 mutants show various alterations in seam cell fates, including
precocious seam fusion and gaps in the adult alae. The latter have been reported in various
retarded heterochronic mutants like let-7 (Slack et al., 2000), which fail to exit the cell cycle.
CKI-1 contributes to cell cycle exit and is upregulated in arresting cells. We observed
cki-1::gfp expression in all seam cells by mid-L4 of wild type worms (n≥15), after seam
cells exit the cell cycle and synthesize the adult alae (Fig. S4J,K). In contrast, cki-1::gfp was
not expressed in the region of the alae gaps in dre-1 mutants (n≥15), even though cells
flanking the gap showed expression. These findings suggest that the alae gaps in dre-1
mutants arise from a failure to exit the cell cycle and differentiate properly.
If CDT-2 were a DRE-1 substrate, then cdt-2 knockdown would be predicted to suppress
dre-1 mutant defects. Depleting cdt-2 levels using RNAi strikingly reduced the appearance
of gaps in the adult alae of dre-1(dh99) mutants from 56% to 13% (Fig. 4F–H).
Interestingly, the precocious seam cell fusion of dre-1(dh99) mutants and a synthetic
gonadal migration defect observed in dre-1(dh99);daf-12(rh61rh411) double mutants were
not affected by cdt-2 depletion (Fig. S4L–S). These results reveal that dre-1 and cdt-2
specifically interact for some developmental processes (adult alae formation) but not others
(seam fusion and gonadal outgrowth).
DISCUSSION
It is believed that substrate recognition subunits of CRL ubiquitin ligases are degraded via
an auto-ubiquitylation process that is promoted by the lack of substrate availability (Lee et
al., 2011; Yen and Elledge, 2008). An exception to this rule is the degradation of the
substrate binding subunits of SCFSKP2, namely, SKP2, which is ubiquitylated and degraded
via the APC/CCDH1 ubiquitin ligase (Bashir et al., 2004; Wei et al., 2004). We now show
that the degradation of a CRL4 substrate receptor (CDT2) is regulated by a SCF ubiquitin
ligase (SCFFBXO11). In proliferating cells, this event is inhibited by the CDK-dependent
phosphorylation of CDT2 on Thr464, which is present in the FBXO11 binding domain of
CDT2. Thus, in contrast to other F-box proteins, which bind substrates only when they are
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phosphorylated in their degrons, FBXO11 behaves in the opposite way, dissociating from
the substrate when the degron is phosphorylated. This identifies a novel mechanism for
regulation of substrate recognition by an F-box protein.
Significantly, we found that CDT2 phosphorylation on Thr464 and CDT2 stability decrease
when cells exit the cell cycle. The decrease in CDT2 protein levels is mediated by
SCFFBXO11, and inhibition of this event produces a delay in cell cycle exit. In serumstarved
cells containing high levels of CDT2, we observed a consistent decrease in SET8 levels, but
decreases in the levels of the other two CDT2 substrates (i.e., CDT1 and p21) were less
consistent. The reason for this differential effect is currently not known.
In worms, cdt-2 depletion suppresses the appearance of gaps in the adult alae of dre-1
mutants. Conceivably, these gaps could occur as a consequence of delayed cell cycle exit of
seam cells, which then fail to execute adult-specific cellular differentiation programs on
schedule (Slack et al., 2000). This hypothesis is supported by the lack of cki-1::gfp
expression, a marker for arresting cells, in the epidermal tissues underlying the alae gaps.
The physical interaction between CDT-2 and DRE-1, and the genetic interactions observed
in C. elegans are consistent with the results in human cells and support a model in which
CDT-2 is a substrate of SCFDRE-1. However, the observation that cdt-2 depletion cannot
rescue the precocious seam cell fusion even or the synthetic gonadal migration present in the
dre-1 suggests that accumulation of distinct SCFDRE-1 substrates is responsible for the
diverse heterochronic phenotypes of dre-1 mutants.
In summary, our findings indicate that the FBXO11/DRE-1-dependent degradation of
CDT2/CDT-2 is part of a highly conserved cellular program that controls the timing of cell
cycle exit and differentiation. In the future, it will be important to determine the specific
cellular context under which mammalian CDT2 is degraded to control developmental and
cell differentiation.
EXPERIMENTAL PROCEDURES
Cell Lines, Serum Starvation, and Drug Treatments
HeLa, RPE1-hTERT, HEK293T, and HaCaT, cells were maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum (FBS). Cells were starved for the
indicated time periods in 0.1% serum. The following drugs were used: MG132 (Peptides
International; 10 mM), cycloheximide (Sigma; 100 mg/ml), recombinant TGF-β (Cell
Signaling, 5 ng/ml), RO3306 (Tocris, 20 µM), Roscovitine (Cell Signaling, 10 µM), pp242
(Sigma, 2.5 µM), PD98059 (Cell Signaling, 20 µM), D4476 (Calbiochem, 50 µM), GSK3i
IX (Calbiochem, 5 µM), DMAT (Sigma, 200 nM), LY293646 (Millipore, 1 µM), UO126
(Cell Signaling, 30 µM), SB203580 (Calbiochem, 10 µM).
Antibodies
The following Rabbit polyclonal antibodies were used: FBXO11 (Novus Biological), CDT2
(Novus Biological), p21 (Santa Cruz Biotechnology), SET8 (Cell Signaling), phospho
SMAD2 (S465/467) (Cell Signaling), FBXO1 (C-20; Santa Cruz Biotechnology), FBXO5
(Invitrogen), FBXO31 (Bethyl), FBXL1 (Invitrogen), FBXW1 (Cell Signaling), FBXW7
(Bethyl) anti CUL4 (Rockland/VWR), anti-FLAG (Sigma), phospho p27 (T187)
(Invitrogen), and MYC (Bethyl Laboratories). Antibodies against FBXO18, FBXW9,
FBXL11, cyclin B, and SKP1 were generated and characterized in the Pagano laboratory.
The rabbit polyclonal phosphospecific antibody pCDT2 (T464) was generated using a
peptide containing the sequence DLPLPSNpTPTFSIK. The following mouse monoclonal
antibodies rabbit were used: DDB1 (Invitrogen), PLK1 (Invitrogen), anti-FLAG M2
(Sigma), p27 (BD Biosciences) and anti-HA (Covance).
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Biochemical Methods
Extract preparation, immunoprecipitation, and western blotting were performed as
previously described (Duan et al., 2012; Duan et al., 2011). Cell lysis, immunopurification,
and MS/MS analysis have been previously described (D'Angiolella et al., 2012). In Vitro
Phosphorylation of CDT2 and p27 were performed as previously described for other CDK
substrates (D'Angiolella et al., 2012). CDT2 ubiquitylation was performed in 30 µl reaction
buffer containing 0.1 µM E1, 0.25 µM Ubc3, 0.25 µM Ubc5, 1.5 µg/µl ubiquitin, and 1 µl of
in vitro translated CDT2. Full length FBXO11 or a deletion mutant lacking its N-terminus
that contains the F-box domain FBXO11(ΔFbox) were immunopurified with anti-FLAG M2
affinity gel from transfected HEK293T cells and eluted by competition with FLAG peptide.
Samples were then incubated at 30°C for the indicated times and analyzed by SDS-PAGE
and immunoblotting.
siRNAs and shRNAs
siRNA duplexes were transfected into subconfluent RPE1-hTERT, HeLa and HaCaT cells
using HiPerfect reagent (QIAGEN) according to the manufacturer’s instructions. The Non
Targeting (NT), CDT2 and FBXO11 siRNAs were purchased from Dharmacon (On target
Plus D-001810-10-05, L-020543-00-0005 and L-012428-00-0005, respectively.). The
retroviral vectors expressing shRNA control or against FBXO11 was a gift from Dr. Carroll
(NYU Medical Center).
Mammalian cell Infection
Retrovirus-mediated gene transfer was performed as previously described (D'Angiolella et
al., 2010).
C. elegans RNAi
The strains used in this study were: N2 (Bristol), AA426 dre-1(dh99), VT825
dpy20(e1282);maIs113(cki-1::gfp). RNAi was performed using the feeding protocol as
described (Kamath et al., 2001). Worms were placed on RNAi for one generation before
phenotypic analysis. RNAi efficiency was validated by the observation of cdt-2 knockdown
related phenotypes (Kim et al., 2008), as well as qPCR (data not shown). All experiments
were conducted at 20°C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• FBXO11 targets CDT2, a CRL4 substrate receptor, for proteasomal degradation
• CDK-mediated phosphorylation of CDT2 degron inhibits recognition by
FBXO11
• FBXO11-mediated degradation of CDT2 controls the timing of cell cycle exit
• FBXO11-CDT2 functional interaction is evolutionary conserved from worms to
humans
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Fig. 1. FBXO11 targets CDT2 for ubiquitylation and degradation
(A) Endogenous FBXO11 and endogenous CDT2 associate in HeLa cells. HeLa cells were
transfected with either siRNAs to the indicated mRNAs or a non-targeting siRNA (NT).
Lysates were immunoprecipitated with either an affinity purified polyclonal antibody
against FBXO11, an affinity purified polyclonal antibody to CDT2, or an affinity purified
rabbit IgG and analyzed by immunoblotting, as indicated.
(B) HeLa cells were transfected with either siRNAs to the indicated mRNAs (four different
FBXO11 siRNAs) or a non-targeting siRNA (NT). Cells were collected 48 hours after
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transfection, lysed, and processed for immunoblotting with antibodies to the indicated
proteins.
(C) Silencing of FBXO11 results in the stabilization of CDT2. HeLa cells were transfected
with either an siRNA to FBXO11 or a non-targeting siRNA (NT), before treatment with
cycloheximide (CHX) for the indicated times. Protein extracts were then immunoblotted for
the indicated proteins. Long and short exposures (ex.) are shown for CDT2.
(D) The experiment was performed as in (B).
(E) HEK-293T cells were transfected with HA-tagged CDT2, FLAG-tagged FBXO11,
FLAG-tagged FBXO11(ΔFbox), and/or an empty vector (EV) as indicated. After
immunopurification with anti-FLAG resin, in vitro ubiquitylation of CDT2 was performed
in the presence or absence of E1, E2s, and Ubiquitin (Ub). Where indicated, methylated
ubiquitin (me-Ub) was added. Samples were analyzed by immunoblotting with an anti-
CDT2 antibody. The bracket on the right marks a ladder of bands >100 kDa corresponding
to ubiquitylated CDT2. Immunoblots of whole cell extracts (WCE) are shown at the bottom.
(see also Figure S1 and Table S1).
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Fig. 2. CDT2 is phosphorylated in vivo on Thr464, thereby inhibiting CDT2 binding to FBXO11
(A) List of CDT2 mutants tested for binding to FBXO11. CDT2 mutants that interacted with
endogenous FBXO11 are designated with the symbol (+).
(B) HeLa cells were transfected with either FLAG-tagged CDT2 or the indicated FLAG-
tagged CDT2 mutants. Whole cell extracts (WCE) were immunoprecipitated (IP) with anti-
FLAG resin, and immunocomplexes were immunoblotted as indicated.
(C) HeLa cells were infected with either an empty virus (EV), a retrovirus expressing
FLAG-HA-tagged wild type CDT2 or FLAG-HA-tagged CDT2(T464A). Cells were then
transfected with either an siRNA to FBXO11 or a non-targeting siRNA (NT), before
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treatment with cycloheximide (CHX) for the indicated times. Protein extracts were then
immunoblotted for the indicated proteins.
(D) HeLa cells were transfected with either siRNAs to the indicated mRNAs or a non-
targeting siRNA (NT). Cells were collected 48 hours after transfection, lysed, and processed
for immunoblotting with antibodies to the indicated proteins.
(E) HeLa cell extracts were incubated with beads coupled to the indicated peptide or
phospho-peptide. Beads were extensively washed, and bound proteins were immunoblotted
as indicated.
(F) HeLa cells were transfected with FLAG-tagged FBXO11 or an empty vector (EV).
Whole cell extracts were immunoprecipitated (IP) with anti-FLAG resin and probed with
antibodies to the indicated proteins.
(see also Figure S2)
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Fig. 3. CDT2 is phosphorylated by CDKs
(A) HeLa cells were treated with the indicated kinase inhibitors. Cells were collected four
hours post-treatment, lysed, and immunoblotted as indicated.
(B) HeLa cells were treated with either DMSO or RO-3306. One hour later, cycloheximide
(CHX) was added for the indicated times. Cells were collected, lysed, and immunoblotted as
indicated.
(C) In vitro-translated CDT2 was incubated at 30°C with the indicated kinases. After the
indicated times, the reactions were stopped, and the samples were immunoblotted as
indicated.
(see also Figure S3)
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Fig. 4. FBXO11-dependent CDT2 degradation regulates the timing of cell cycle exit
(A) RPE1-hTERT cells were transfected with either an siRNA to FBXO11 or a non-
targeting siRNA (NT) and serum starved for the indicated times. Protein extracts were
immunoblotted for the indicated proteins.
(B) RPE1-hTERT cells were infected with an empty virus (EV), a retrovirus expressing
FLAG-HA-tagged wild type CDT2, or FLAG-HA-tagged CDT2(T464D). Cells were serum
starved for the indicated times. Protein extracts were immunoblotted for the indicated
proteins.
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(C) HaCaT cells infected as in (B) were serum starved for 24 hours. Whole cell lysates were
then immunoprecipitated with anti-FLAG resin and immunoblotted as indicated.
(D) MDA-MB-231 cells were transfected with either an siRNA to FBXO11 or a non-
targeting siRNA (NT) and treated with TGFβ for the indicated times. Protein extracts were
immunoblotted for the indicated proteins.
(E) The experiment was performed as in (B), except that cells were incubated with EdU for
the last 20 minutes before collection. The percentage of EdU positive cells was determined
by FACS analysis in triplicate experiments. The graph shows the percentage of cells
incorporating EdU normalized to the percentage of cells incorporating EdU prior to serum
starvation, which was set as 100%. Data are represented as mean of three independent
experiments +/− SEM.
(F–G) Adult alae gaps of L4 molt dre-1(dh99) mutants are observed with an empty vector
control (F, arrowheads). These gaps rarely occur when dre-1(dh99) worms are grown on
cdt-2 RNAi (H). Scale bars, 10 µm.
(H) Percentage of dre-1(dh99) mutants with interrupted adult alae at the L4 molt when
grown on L4440 or cdt-2 RNAi, respectively. These data are from four experiments with ≥
20 worms each. Error bars indicate the standard deviation. **p≤0.001.
(see also Figure S4)
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